Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1

Interventions

Magnetic Resonance Spectroscopy 48enzalutamide 46apalutamide 36Specimen Handling 31Androgen Antagonists 30Abiraterone Acetate 29Radiosurgery 26Prednisone 26darolutamide 25Docetaxel 25Pluvicto 21abiraterone 19Radiotherapy 19Biopsy 17Leuprolide 15Surveys and Questionnaires 11Radiation 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11relugolix 10gallium 68 PSMA-11 10cabazitaxel 10acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 10Standard of Care 10Nivolumab 10Triptorelin Pamoate 9Carboplatin 9pembrolizumab 8niraparib 8bicalutamide 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × ferumoxtran-10 × 90 days × Clear all
NCT04261777 2026-04-28

Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

Saving Patients' Lives Medical B.V.

Phase 3 Terminated
172 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡